In-silico ADMET predicated Pharmacoinformatics of Quercetin-3-Galactoside, polyphenolic compound from Azadirachta indica, a sacred tree from Hill Temple in Alagarkovil Reserve Forest, Eastern Ghats, INDIA

M. Sabitha1, K. Krishnaveni2, M. Murugan1, A N Basha1, Gilse A Pallan1, C. Kandeepan1, S. Ramya3, R. Jayakumararaj4

1 PG & Research Department of Zoology, Arulmigu Palaniandavar College of Arts & Culture, Palani – 624601, TamilNadu, India
2 Department of Zoology, GTN College, Dindigul, TamilNadu, India
3 Department of Botany, Government Arts College, Melur – 625106, Madurai, TamilNadu, India

Abstract

Quercetin (3,4′,5,7-Pentahydroxyflavone) is the one among the bioactive secondary metabolite (BASM) in neem seed of Azadirachta indica A. Juss. Quercetin (Que) and its derivatives hold promising pharmacological effects. Antidiabetic, anti-inflammatory, antioxidant, antimicrobial, anti-Alzheimer’s, antiarthritic, cardiovascular, and wound-healing effects of Que have been extensively investigated, recently lot of work has been carried out on its anticancer activity against different cancer cell lines. Recently, in silico/in vitro studies have demonstrated that Que interferes with different stages of coronavirus entry and replication cycle (PLpro, 3CLpro, and NTPase/helicase). Due to its pleiotropic effects in human health and disease and lack of systemic toxicity, Que and its derivatives could be tested for their efficacy on human target system in future clinical trials. In the present study, an attempt has been made to evaluate the physicochemical, druggable properties of Que from A. indica to prospect its ADMET properties.

Keywords: NEEM; Azadirachta indica; Quercetin; Pharmacoinformatics; ADMET; Drug-Likeness; Toxicology

INTRODUCTION

Azadirachta indica A. Juss commonly known as Neem belongs to the family Meliaceae1-3. Popular as natural store-house of phyto-drugs it has been exploited for its medicinal properties since the dawn of civilization4,5. Neem is a versatile plant across the country for its use in Indigenous/Traditional Systems of Medicine. A. indica has its origin from India however, common in South East Asian (SEA) Region (Bangladesh, Sri Lanka, Bhutan, Myanmar, Pakistan, and Nepal)6. Recently, it has been disseminated world over, (tropical and sub-tropical regions)7.

Neem, a perennial, medium-sized (10 - 15 m) fast-growing tree needs an optimum temperature of 40-50 °C, annual rainfall (400 – 800 mm/annum) and grows well in poor/ degraded/ mined soils. Being repository of bioactive secondary metabolites Neem tree remains as the ideal target for research. As most of the secondary metabolite are

localised in leaves/ seeds, destruction of the plant is not warranted. Almost all of the bioactive secondary metabolites in Neem are therapeutic, eco-friendly and biodegradable in nature, therefore GRAS to man and environment8,9. The most active constituent is azadirachtin, besides others viz., nimbolin, nimbim, nimbin, nimbidol, sodium nimbinate, gedunin, salannin, and quercetin. Leaves contain BASM such as nimbin, nimbanene, 6-desacetylnimbimine, nimbandiol, nimboldol, ascorbic acid, n-hexacosanol, 7-desacetyl-7-benzoylazadiradione, 7-desacetyl-7-benzoylgedunin, 17-hydroxyazadiradione, and nimbin10,11. Quercetin and β-sitosterol, polyphenolic flavonoids, obtained from fresh leaves have significant antibacterial and antifungal properties12,13. Quercetin and β-sitosterol, polyphenolic flavonoids, obtained from fresh leaves have significant antibacterial and antifungal properties12,13.

Since antiquity all parts of the plant, including root, stem, bark, leaves, fruits, and seeds are used to cure various ailments in humans and domestic animals therefore, Neem has been considered as multi-purposes village dispensary14-15.
In fact, therapeutic applications attributed to Neem include abortive, analgesic, antibacterial, anticancer, antidiabetic, antifungal, anti-helminthic, anti-hyperglycemic, anti-inflammatory, antimalarial, antipyretic, antispasmodic, anti-spermatogenic, antiviral, diuretic, hyper-cholesteremic, immuno-modulatory, mouth-wash, contraception, dental plaque, head lice, heart disease, insect repellent, malaria, pesticide, psoriasis, skin diseases, wound healing, gastrointestinal ailments, SARS-CoV-2 26-59.

Que - aglycone is able to conjugate with glucose, xylose, or rutinoside attaching to one of the Que’s hydroxyl groups with the consequent creation of various Que glycoside forms. Quercetin-3-O-glycoside is present as a pigment in flowers, vegetables, and fruits; as glycosides rather than as aglycones. Que exhibits higher bioavailability than other phytochemicals. Main sources of Que include grapes, berries, cherries, apples, citrus fruits, onions, buckwheat, kale, tomatoes, red wine, and black tea. However, the concentration of Que varies from one plant to another sometimes in different parts of the same plant even. Que, is powerful antioxidant than vitamins C and E. Que and its derivatives regulate cell cycle progression and cellular signal transduction pathway. Metabolic plasticity of Que is the key determinant in the plant adaptive reaction, Que aglycones are effective regulators of auxin transport, growth and development in plant systems. In animal system - anti-inflammatory and antioxidant effects of Que regulate oxidative, kinase, and cell cycle inhibitor activity, apoptosis-inducing effect holds anticancer potential. Furthermore, Que exerts a remarkable effect on cellular immunity and localised inflammation60. Recently, it has been reported that abundance of Que in different plant parts of Artemisia annua may be exploited for the treatment of coronavirus61. With this background information pharmacological characterization is expected to further validate Que as novel drug lead62-64.

MATERIALS AND METHODS

**Class**: Equisetopsida C. Agardh

**Subclass**: Magnoliidae Novák Ex Takht.

**Superorder**: Rosanae Takht.

**Order**: Sapindales Juss. Ex Bercht.

**Family**: Meliaceae Juss.

**Genus**: Azadirachta A. Juss.

**Species**: Azadirachta indica A. Juss.

**Common Name**: Neem

**Vernacular Name**: Vempamaram (Tamil)

**Botanical Description**: Tree, up to 15 m tall. Branches glabrous; Leaves imparipinnate, pulvinus at the base; leaflets alternate opposite to opposite, 2.5 - 7.0 cm long, 1.5 - 4.0 cm broad, ovate, subsecisile, acuminate; Flowers white, sweet-scented; Sepals obovate, 1.5 mm long, puberulous, imbricate. Petals 6 mm long, obvoate to oblong, white, margin ciliate; Staminal tube 5 mm long, puberulous, 10-striate, 10-toothed; teeth 2-lobed; anthers oblong, basifixed; Ovary sub-globose; style linear 2.5 mm long; stigma trilid. Fruit: Drupe oblong, 1.3 - 2.0 cm long, greenish-yellow, Seed: 1-seeded. Plants were collected from the fields in the wild Alagar Hills, Eastern Ghats, INDIA as described previously63.

**GC-MS Analysis**

Neem Seed Oil Extracts of A. indica was obtained from the seed samples collected from the foothills of Alagar Hills, Alagarkoil Reserve Forest, Dindigul District, Tamil Nadu, India. Phyto-components were identified using GC-MS detection system as described previously, however with modification, whereby portion of the extract was analysed directly by headspace sampling. GC-MS analysis was accomplished using an Agilent 7890A GC system set up with 5975C VL MSD (Agilent Technologies, CA, USA). Capillary column used was DB-5MS (30×0.25 mm, film thickness of 0.25 μm; J&W Scientific, CA, USA). Temperature program was set as follows: initial temperature 50°C held for 1 min, 5°C per min to 100°C, 9°C per min to 200°C held for 7.89 min, and the total run time was 40 min. The flow rate of helium as a carrier gas was 0.811851 mL/ min. MS system was performed in electron ionization (EI) mode with Selected Ion Monitoring (SIM). The ion source temperature and quadrupole temperature were set at 230°C and 150°C, respectively. Identification of phyto-components was performed by comparison of their retention times and mass with those of authentic standards spectra using computer searches in NIST 08.L and Wiley 7n.l libraries64-65.

**ADMET Prediction**

PubChem database was applied to get the smiles structures of the natural compounds, and was further used for the ADMET prediction. The qualitative assessment of pharmacokinetics viz; absorption, distribution, metabolism, excretion and toxicity (ADMET) profile of selected compounds were predicted computationally using SwissADME and toxicity prediction using T0PKAT (Accelrys, Inc., USA). QikProp develops and employs QSAR/QSPR models using partial least squares, principal component analysis and multiple linear regression to predict physico-chemical significant descriptors66-70.
RESULTS AND DISCUSSION

Physicochemical Properties

The molecular weight of AZA was 720.72 (g/mol); the calculated LogP value was -0.20; LogD - 0.14; LogSw - 4.34. The total number of stereo-centers in the molecule was 16; the stereo-chemical complexity of the molecule was 0.457; the calculated Psip3 value of AZA was 0.771; The overall calculated Topological polar surface area of AZA was 215.34(A2). Likewise the calculated number of hydrogen bond donors in the molecule was 3; whereas the number of hydrogen bond acceptors was 16; the number of smallest set of smallest rings (SSSR) in the molecule analyzed was 2; the size of the biggest system ring in the molecule was 15; similarly, the total number of rotatable bonds in the molecule was 6; the number of rigid bonds was 38; the number of charged groups was 0; similarly the total charge of the compound was 0; the number of carbon atoms in the molecule was 35; whereas the number of heteroatoms in AZA was calculated as 16; the number of heavy atoms in the molecule was calculated as 51; the ratio between the number of non-carbon atoms and the number of carbon atoms in the compound was 0.46 (Fig. 1).

Druggability Properties

Lipinski’s rule of 5 violations of the molecule was 2; Veber rule was Low for the molecule; similarly Egan rule for the molecule was also Low; the Oral PhysChem score (Traffic Lights) for the molecule was recorded as 5; GSK’s 4/400 score for the molecule was Good; Pfizer’s 3/75 score for the molecule was Good; Weighted quantitative estimate of drug-likeness (QEDw) score for the molecule was 0.164; Solubility Forecast Index was Good and the solubility score was 9441.49;

ADMET Properties

Only when the ADME/Tox properties of a drug like compound are of high quality, and when the target has been validated, the compound could be developed into a pharmacrug. In silico drug-likeness evaluation of Azadirachtin for Human Intestinal Absorption (HIA+) value had a probability of 0.890; Blood Brain Barrier (BBB-) value for the molecule had a probability of 0.773; Caco-2 permeable (Caco2-) value for the molecule had a probability of 0.711 (Fig. 4); P-glycoprotein substrate (Substrate) value for the molecule had a probability of 0.835; P-glycoprotein inhibitor 1 (Inhibitor) value for the molecule had a probability of 0.672; P-glycoprotein inhibitor II (Non-inhibitor) value for the molecule had a probability of 0.534. CYP450 2C9 substrate (Non-substrate) value for the molecule had a probability of 0.857; CYP450 2D6 substrate (Non-substrate) - 0.872; CYP450 3A4 substrate (Substrate) - 0.714; CYP450 1A2 inhibitor (Non-inhibitor) - 0.887; CYP450 2C9 inhibitor (Non-inhibitor) - 0.845; CYP450 2D6 inhibitor (Non-inhibitor) - 0.944; CYP450 2C19 inhibitor (Non-inhibitor) - 0.833; CYP450 3A4 inhibitor (Non-inhibitor) - 0.770; CYP450 inhibitory promiscuity (Low CYP Inhibitory Promiscuity) - 0.806; Ames test (Non AMES toxic) - 0.756; Carcinogenicity (Non-carcinogens) - 0.946; Biodegradation (Not ready biodegradable) - 1.000; Rat acute toxicity (4.348 LD50, mol/kg) - PNA; hERG inhibition (predictor I) (Weak inhibitor) - 0.992; hERG inhibition (predictor II) (Non-inhibitor) - 0.569 respectively. Computational methods for analysing and estimating the toxicity of natural bioactive compounds are considered as useful tool for validation as it provides in-depth understanding of toxicogenomics. Therefore, determining the toxicity of BASM in-silico is warranted to identify their potential harmful effects on humans, animals, plants, besides the environment as in-vivo animal tests are constrained by time, ethical considerations, and financial burden. Data pertaining to the descriptors viz., Toxicity, Environmental toxicity, Tox21 pathway and Toxicophore Rules for Azadirachtin are summarized in Table 2. Furthermore, GPCR ligand, ion channel modulator, kinase inhibitor, nuclear receptor ligand, protease inhibitor, enzyme inhibitor score for AZA were calculated as -0.71; -1.51; -1.46; -0.67; -0.35 and -0.71 respectively (Fig. 3). Swiss Target Prediction towards Macrophage migration inhibitory factor, Heat shock protein (HSP 90-alpha), Kappa Opioid receptor, Mu opioid receptor, Delta opioid receptor, Thrombin, Squalene synthetase, Glycogen synthase kinase-3 beta, Glycogen synthase kinase-3 alpha, Protein kinase C alpha, Apoptosis regulator Bcl-X, HMG-CoA reductase, Zinc finger protein GLI1, Proto-oncogene c-JUN, Vanillloid receptor for the compound has been provided in Table 4. Chemical and biological investigations on Azadirachta indica bioactive compounds indicates that the compound is safe for use as a drug molecule3,72-74.

CONCLUSION

The present study is an example to insights into the broad scope of pharmacoinformatics of Quercetin-3-Galactoside, a polyphenolic compound from Azadirachta indica (Neem), with an emphasis on plant based natural product drug discovery. The study indicates that plant based natural products still possess an extraordinary challenge that has to be solved before taken for drug development. However, it is anticipated that as more quality data on natural product research, such as bio-activity, biomolecularinformatics, cheminformatics, toxicoinformatics integrated together with new IoT data mining, algorithms and machine learning techniques to accelerate natural product based drug discovery. Furthermore, online databases serve as attractive sources for identifying novel natural product scaffolds with promising drug-like
properties in NPs which is expected to accelerate the pace of Drug Discovery.

REFERENCES

1. Kalivani T, Meignanam E, Premkumar N, Siva R, Vijayakumar V, Rajasekaran C, Ramya S, Jayakumararaj R. Studies on hepatoprotective properties of leaf extracts of Azadirachta indica A. Juss (Meliaceae). Ethnobotanical Leaflets 2009; 2009(1):20.

2. Schmutterer H, Ascher KR. Neem tree (Azadirachta indica A. Juss.) and other meliaceous plants VCH; 199.

3. Loganathan T, Barathinivas A, Soorya C, Balamurugan S, Nagajothi TG, Jayakumararaj R. GCMS Profile of Bioactive Secondary Metabolites with Therapeutic Potential in the Ethanolic Leaf Extracts of Azadirachta indica--A Sacred Medicinal Plant of INDIA. Journal of Drug Delivery and Therapeutics. 2021; 11(4-5):119-26. https://doi.org/10.22270/jddt.v11i4-S.4967

4. Zeenat F, Ravish MS, Ahmad W, Ahmad I. Therapeutic, phytochemistry and pharmacology of Azadirachta indica: A review. Int J Unani Integr Med. 2018; 2(1):20-8.

5. Biswas K, Chattopadhyay I, Banerjee RK, Bandypadhyay U. Biological activities and medicinal properties of neem (Azadirachta indica). Current Science. 2002; 83:136-45.

6. Negi PS, Jayaprakash GK, Jena BS. Distribution and introduction cultivation state of Azadirachta indica Phytochemistry. 1971; 18:199.

7. Yan, ping ZH, Yong, qi LA, Xing, ming PE, Juan LL. Global Distribution and Introduction Cultivation State of Azadirachta indica [J]. Forest Inventory and Planning. 2002; 3(2-9).

8. Ramya S, & Jayakumararaj R. GCMS Profil of bioactive compounds from Azadirachta indica A. Juss leaves using HPLC. Pharmaceutical Sciences. 2019; 81(2):326

9. Islas JF, Acosta E, Zuca G, Delgado

10. Rahma

11. Siddiqui BS, Afshan F, Faizi S, Naqvi SN, Tariq BM. Two insecticidal tetranortriterpenoids from Azadirachta indica Phytochemistry. 2000; 53(3):371-6. https://doi.org/10.1016/S0031-9422(99)00548-8

12. Arevolu OO, Obafeye RO, Ayodele BS. Optimization of solvent extraction of oil from neem Azadirachta indica and its characterization. Journal of Scientific Research and Reports. 2013; 10:304-314 https://doi.org/10.1074/jsr/2013/3705

13. Agrawal S, Popli DB, Sircar K, Chowdhry A. A review of the anticancer activity of Azadirachta indica (Neem) in oral cancer. Journal of Oral Biology and Craniofacial Research. 2020 Apr 1; 10(2):266-9. https://doi.org/10.1016/j.jobcr.2020.04.007

14. Agrawal S, Popli DB, Sircar K, Chowdhry A. A review of the anticancer activity of Azadirachta indica (Neem) in oral cancer. Journal of Oral Biology and Craniofacial Research. 2020 Apr 1; 10(2):266-9. https://doi.org/10.1016/j.jobcr.2020.04.007

15. Muhammad A, Kacheke MA, NEEM, Azadirachta indica LA (A. Juss): an eco-friendly botanical insecticide for managing farmers 'insects pest problems - a review. PUDM Journal of Sciences. 2020; 4(4):484-91. https://doi.org/10.33003/jjs-2020-0404-506

16. Benelli G, Canale A, Tonioio C, Higuchi A, Murugan K, Pavela R, Nicolletti M. Neem (Azadirachta indica): towards the ideal insecticide?. Natural product research. 2017; 31(4):369-86. http://dx.doi.org/10.1080/14786419.2016.1218434

17. Schmutterer H. Properties and potential of natural pesticides from the neem tree, Azadirachta indica Annual review of entomology. 1996; 35(1):271-97. http://dx.doi.org/10.1146/annurev.en.35.010190.001415

18. Gupta SC, Prasad S, Tyagi AK, Kunnumakkara AB, Aggarwal BB. Neem (Azadirachta indica): An Indian traditional panacea with modern molecular basis. Phytochemistry. 2017; 34:14-20. https://doi.org/10.1016/j.phytochem.2017.07.001

19. Hashmat I, Azad H, Ahmed A, Neem (Azadirachta indica A. Juss) - A nature's drugstore: an overview. Int Res J Biol Sci. 2012; 1(6):76-9.

20. Ramya S, Neethirajan K & Jayakumararaj R. Profile of bioactive compounds in Syzygium cumini-a review. J. Pharm. Res 2012; 5(8):4548-4553.
Figure 1: 2D, 3D, Physicochemical and Boiled-Egg Prediction of Quercetin-3 Galactoside
Table 1 Physicochemical, Druggability, ADMET properties of Quercetin-3 Galactoside

| PHYSICOCHEMICAL PROPERTIES                                      | VALUE              |
|-----------------------------------------------------------------|--------------------|
| Molecular weight                                                | 464.38 g/mol       |
| LogP                                                            | -0.54              |
| LogD                                                            | -1.16              |
| LogSw                                                           | -2.91              |
| Number of stereo enters                                         | 5                  |
| Stereo-chemical complexity                                      | 0.238              |
| Fsp3                                                            | 0.286              |
| Topological polar surface area                                  | 210.51 Å²          |
| Number of hydrogen bond donors                                  | 8                  |
| Number of hydrogen bond acceptors                               | 12                 |
| Number of smallest set of smallest rings (SSSR)                 | 3                  |
| Size of the biggest system ring                                  | 10                 |
| Number of rotatable bonds                                       | 4                  |
| Number of rigid bonds                                           | 24                 |
| Number of charged groups                                        | 0                  |
| Total charge of the compound                                    | 0                  |
| Number of carbon atoms                                          | 21                 |
| Number of heteroatoms                                           | 12                 |
| Number of heavy atoms                                           | 33                 |
| Ratio between the number of non-carbon atoms and the number of carbon atoms | 0.57               |

| DRUGGABILITY PROPERTIES                                        | VALUE              |
|-----------------------------------------------------------------|--------------------|
| Lipinski's rule of 5 violations                                  | 2                  |
| Veber rule                                                      | Good               |
| Egan rule                                                       | Good               |
| Oral PhysChem score (Traffic Lights)                            | 3                  |
| GSK's 4/400 score                                               | Good               |
| Pfizer's 3/75 score                                             | Good               |
| Weighted quantitative estimate of drug-likeness (QEDw) score    | 0.288              |
| Solubility                                                      | 25415.67           |
| Solubility Forecast Index                                       | Good Solubility    |

| ADMET PROPERTIES                                               | VALUE | PROBABILITY |
|----------------------------------------------------------------|-------|-------------|
| Human Intestinal Absorption                                    | HIA+  | 0.786       |
| Blood Brain Barrier                                            | BBB-  | 0.698       |
| Caco-2 permeable                                               | Caco2-| 0.940       |
| P-glycoprotein substrate                                       | Substrate | 0.591           |
| P-glycoprotein inhibitor I                                     | Non-inhibitor | 0.878         |
| P-glycoprotein inhibitor II                                    | Non-inhibitor | 0.797         |
| CYP450 2C9 substrate                                            | Non-substrate  | 0.812         |
| CYP450 2D6 substrate                                            | Non-substrate  | 0.892         |
|                          | CYP450 3A4 substrate | CYP450 1A2 inhibitor | CYP450 2C9 inhibitor | CYP450 2D6 inhibitor | CYP450 2C19 inhibitor | CYP450 3A4 inhibitor | CYP450 inhibitory promiscuity | Ames test | Carcinogenicity | Biodegradation | Rat acute toxicity | hERG inhibition (predictor I) | hERG inhibition (predictor II) |
|--------------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|-------------------------------|-----------|-----------------|---------------|------------------|-----------------------------|-----------------------------|
|                          | Non-substrate        | Non-inhibitor        | Non-inhibitor        | Non-inhibitor        | Non-inhibitor        | Non-inhibitor        | Low CYP Inhibitory Promiscuity | AMES toxic | Non-carcinogens | Not ready biodegradable | 2.387 LD50, mol/kg | Weak inhibitor           | Non-inhibitor             |
|                          | 0.604                | 0.908                | 0.930                | 0.951                | 0.929                | 0.919                | 0.773                         | 0.578                 | 0.959           | 0.626          | Not applicable    | 0.981                        | 0.687                      |

Physicochemical properties were computed using FAF-Drugs4 (28961788) and RDKit open-source cheminformatics platform. The druggability scoring schemes were computed using FAF-Drugs4 (28961788) and FAF-QED (28961788) open-source cheminformatics platform. ADMET features were predicted using admetSAR (23092397) open-source tool.